Published in Clin Pharmacokinet on January 01, 2007
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol (2008) 1.32
Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res (2009) 1.09
Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab (2011) 0.99
Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur J Hum Genet (2009) 0.95
Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res (2015) 0.94
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet (2016) 0.93
Thiopurines in inflammatory bowel disease revisited. World J Gastroenterol (2013) 0.88
Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy. Br J Pharmacol (2010) 0.84
Unusual causes of papilledema: Two illustrative cases. Surg Neurol Int (2013) 0.83
Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. Clin Pharmacol Ther (2016) 0.82
Imputation of TPMT defective alleles for the identification of patients with high-risk phenotypes. Front Genet (2014) 0.81
Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. Br J Clin Pharmacol (2014) 0.79
Response to medical treatment in patients with Crohn's disease: the role of NOD2/CRAD15, disease phenotype, and age of diagnosis. Dig Dis Sci (2009) 0.79
Pretreatment determination of TPMT--state of the art in clinical practice. Eur J Clin Pharmacol (2009) 0.79
Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: a meta-analysis of three genome-wide association studies. Clin Pharmacol Ther (2016) 0.78
Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease. Ann Gastroenterol (2012) 0.77
Interruption of mesalamine and reduction of the blood concentration of the active metabolites of azathioprine: possible causes of ulcerative colitis relapse. Dig Dis Sci (2008) 0.77
Challenges in pharmacogenetics. Eur J Clin Pharmacol (2013) 0.76
Thiopurine treatment in inflammatory bowel disease. Clin Pharmacokinet (2007) 0.75
How I treat my inflammatory bowel disease-patients with thiopurines? World J Gastrointest Pharmacol Ther (2016) 0.75
Pharmacogenomics: personalizing pediatric heart transplantation. Circulation (2015) 0.75
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther (2013) 3.81
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol (2012) 3.61
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol (2008) 3.53
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 3.36
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology (2003) 2.97
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther (2004) 2.68
Metformin improves healthspan and lifespan in mice. Nat Commun (2013) 2.68
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology (2009) 2.59
Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to hypertension. Hypertension (2004) 2.32
Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics (2004) 2.32
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem (2008) 2.24
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results. Nephrol Dial Transplant (2008) 2.09
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2003) 2.06
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics (2005) 1.95
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis (2010) 1.91
The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia (2008) 1.91
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ (2002) 1.88
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 1.87
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics (2007) 1.84
Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem (2008) 1.84
Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis (2002) 1.80
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA (2005) 1.74
The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol (2007) 1.73
Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol (2006) 1.73
Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol (2003) 1.72
Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol (2011) 1.69
Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. N Engl J Med (2015) 1.68
Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem (2010) 1.66
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther (2008) 1.62
CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat (2003) 1.59
Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol (2002) 1.59
Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther (2002) 1.57
Sex is a major determinant of CYP3A4 expression in human liver. Hepatology (2003) 1.57
The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol (2008) 1.56
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics (2008) 1.52
Proximal femur fracture in older patients--rehabilitation and clinical outcome. Age Ageing (2003) 1.51
CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res (2010) 1.49
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res (2013) 1.49
Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol (2008) 1.49
Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics (2004) 1.42
Intestinal absorption, metabolism, and excretion of (-)-epicatechin in healthy humans assessed by using an intestinal perfusion technique. Am J Clin Nutr (2013) 1.41
Vulnerability of the fetal primate brain to moderate reduction in maternal global nutrient availability. Proc Natl Acad Sci U S A (2011) 1.39
Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol (2005) 1.37
Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics (2009) 1.36
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther (2004) 1.33
CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol (2004) 1.33
Pharmacogenomics of tamoxifen therapy. Clin Chem (2009) 1.31
Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet (2007) 1.31
Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation (2008) 1.30
Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology (2006) 1.29
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol (2002) 1.28
Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol (2005) 1.27
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol (2008) 1.26
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther (2003) 1.23
Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res (2011) 1.21
Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol (2002) 1.21
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol (2005) 1.21
Glucocorticoid exposure at the dose used clinically alters cytoskeletal proteins and presynaptic terminals in the fetal baboon brain. J Physiol (2002) 1.19
Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res (2010) 1.19
Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res (2008) 1.17
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis (2009) 1.16
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med (2002) 1.16
Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int (2002) 1.15
Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol (2005) 1.15
Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics (2006) 1.14
Omics and drug response. Annu Rev Pharmacol Toxicol (2012) 1.14
Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol (2003) 1.14
Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci (2012) 1.14
Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol (2013) 1.13
Age-related changes in pharmacokinetics. Curr Drug Metab (2011) 1.13
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One (2011) 1.12